SetLance

SetLance is an Italian biotechnology company specializing in the discovery and development of peptide-based therapeutics for infectious diseases and oncology. As a spin-off from the University of Siena, the company utilizes a proprietary platform to design multivalent synthetic peptides with enhanced stability and biological activity. The primary focus of the company is addressing the urgent global need for new treatments against multi-drug resistant (MDR) Gram-negative bacteria. Its lead candidate, SET-M33, is a synthetic antimicrobial peptide that has demonstrated efficacy in treating lung infections associated with cystic fibrosis. SetLance operates within the Toscana Life Sciences incubator, benefiting from a collaborative research environment.